Me’s privacy ombudsman secured court approval to retain WilmerHale in the DNA testing company’s Chapter 11 case despite an ...

Regeneron will not acquire 23andMe’s telehealth subsidiary, Lemonaid Health, which the company purchased for approximately $400 million in 2021.

Regeneron Pharmaceuticals on Monday announced plans to purchase genetic testing company 23andMe for $256 million.. The New York-based drugmaker is set to take over 23andMe after winning a ...

23andMe, the genetic testing company that was once valued at $6 billion but filed for bankruptcy in March, will be bought by Regeneron Pharmaceuticals, a biotechnology company that has used DNA ...

CT is your last chance to file a claim with 23andMe for a 2023 data breach that may have compromised your genetic data.

Regeneron said Monday morning that it had agreed to buy most of the consumer genetic-testing firm 23andMe out of bankruptcy for $256 million. It’s a very strange deal.

Biotechnology leader Regeneron Pharmaceuticals is acquiring genetic testing firm 23andMe for $256 million following its bankruptcy filing. The deal excludes 23andMe’s telehealth subsidiary ...

Regeneron’s deal to acquire 23andMe is still subject to approval in the U.S. Bankruptcy Court for the Eastern District of Missouri. A hearing in the case was scheduled for June 17.

Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's privacy policies.

Regeneron to acquire nearly all of 23andMe’s assets for $256M, marking a new chapter for the direct-to-consumer genetic testing pioneer. genprowebdirectory Facebook Linkedin RSS Twitter Youtube ...

Biotechnology leader Regeneron Pharmaceuticals is acquiring genetic testing firm 23andMe for $256 million following its bankruptcy filing. The deal excludes 23andMe’s telehealth subsidiary ...